New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia

Luca Laurenti; Laura De Padua; G D'Arena; Barbara Vannata; Idanna Innocenti; Michela Tarnani; S Deaglio; Simona Sica; Dg Efremov; Giuseppe Leone

New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia

Luca Laurenti, Laura De Padua, G D'Arena, Barbara Vannata, Idanna Innocenti, Michela Tarnani, S Deaglio, Simona Sica, Dg Efremov, Giuseppe Leone

Risultato della ricerca: Contributo in rivista › Articolo in rivista

2 Citazioni (Scopus)

Abstract

Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.

Lingua originale	English
pagine (da-a)	508-518
Numero di pagine	11
Rivista	MINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume	11
Stato di pubblicazione	Pubblicato - 2011

Keywords

Antibodies, Monoclonal
Antigens, CD
Antigens, CD20
Antigens, CD40
Antigens, Neoplasm
Antineoplastic Agents
Glycoproteins
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Receptors, IgE
Tetraspanins

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{77551dd7a05f4c819d9989fb6b744347,

title = "New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia",

abstract = "Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.",

keywords = "Antibodies, Monoclonal, Antigens, CD, Antigens, CD20, Antigens, CD40, Antigens, Neoplasm, Antineoplastic Agents, Glycoproteins, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Receptors, IgE, Tetraspanins, Antibodies, Monoclonal, Antigens, CD, Antigens, CD20, Antigens, CD40, Antigens, Neoplasm, Antineoplastic Agents, Glycoproteins, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Receptors, IgE, Tetraspanins",

author = "Luca Laurenti and {De Padua}, Laura and G D'Arena and Barbara Vannata and Idanna Innocenti and Michela Tarnani and S Deaglio and Simona Sica and Dg Efremov and Giuseppe Leone",

year = "2011",

language = "English",

volume = "11",

pages = "508--518",

journal = "MINI-REVIEWS IN MEDICINAL CHEMISTRY",

issn = "1875-5607",

publisher = "Hilversum : Bentham Science Publishers",

}

TY - JOUR

T1 - New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia

AU - Laurenti, Luca

AU - De Padua, Laura

AU - D'Arena, G

AU - Vannata, Barbara

AU - Innocenti, Idanna

AU - Tarnani, Michela

AU - Deaglio, S

AU - Sica, Simona

AU - Efremov, Dg

AU - Leone, Giuseppe

PY - 2011

Y1 - 2011

N2 - Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.

AB - Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.

KW - Antibodies, Monoclonal

KW - Antigens, CD

KW - Antigens, CD20

KW - Antigens, CD40

KW - Antigens, Neoplasm

KW - Antineoplastic Agents

KW - Glycoproteins

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Receptors, IgE

KW - Tetraspanins

KW - Antibodies, Monoclonal

KW - Antigens, CD

KW - Antigens, CD20

KW - Antigens, CD40

KW - Antigens, Neoplasm

KW - Antineoplastic Agents

KW - Glycoproteins

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Receptors, IgE

KW - Tetraspanins

UR - http://hdl.handle.net/10807/5025

M3 - Article

SN - 1875-5607

VL - 11

SP - 508

EP - 518

JO - MINI-REVIEWS IN MEDICINAL CHEMISTRY

JF - MINI-REVIEWS IN MEDICINAL CHEMISTRY

ER -

New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia

Abstract

Keywords

Altri file e collegamenti

Fingerprint

Cita questo